Displaying 2361 - 2380 of 4770
1604007 Informal Interpretation
Date
Rule
801.1(o), 801.2(g), 801.13
The parties may file separate HSRs for each entirely separate transaction, and may close once the relevant waiting period expires or early termination is granted (even if the other transaction is...
File
Original Image
(44.79 KB)
1604005 Informal Interpretation
Date
Rule
801.10, 801.13, 801.14
For the 90% being acquired, if the acquisition/tender price is determined (as it sounds to be), then the value is the greater of the market price (the lowest closing quotation, or, in an interdealer...
File
Original Image
(37.83 KB)
FTC and Justice Department Officials Meet with Officials of Chinese Antitrust Agencies
Date
Federal Trade Commission Chairwoman Edith Ramirez and Assistant Attorney General Bill Baer of the U.S. Department of Justice’s Antitrust Division participated in high level bilateral meetings with...
1604006 Informal Interpretation
Date
Rule
Item 1(f)
It should be 90% indirect ownership.
File
Original Image
(38.19 KB)
1604004 Informal Interpretation
Date
Rule
801.2
There would be 2 filings here: B1 acquiring X from T B2 acquiring Y from T based on a continuum theory
File
Original Image
(43.88 KB)
1604003 Informal Interpretation
Date
Rule
802.2(c)
You use the LogCo net revenues (which are gross revenue minus returns, discounts and allowances, but not minus costs – see informal interp 1509005) because Logco (the entity with third party sales) is...
File
Original Image
(81.6 KB)
FTC, DOJ Issue Joint Statement on Preserving Competition in the Defense Industry
Date
The Federal Trade Commission and the Department of Justice today issued a joint statement reaffirming the importance of preserving competition in the defense industry. The statement describes the...
FTC Workshop Will Examine Competition and Consumer Protection Issues in the Rooftop Solar Business
Date
The Federal Trade Commission will hold a workshop in Washington, DC, on June 21, 2016, to examine competition and consumer protection issues raised by consumers’ growing use of rooftop solar panels to...
1604002 Informal Interpretation
Date
Rule
801.1, 801.2, 802.31
A put-call arrangement that does not transfer beneficial ownership is not reportable.
File
Original Image
(35.72 KB)
Endo Pharmaceuticals / Impax Labs
The FTC filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm with an agreement not to market an authorized generic – often called a “no-AG commitment” – as a form of reverse payment. The complaint, filed in the Eastern District of Pennsylvania, alleges that Endo paid the first generic companies that filed for FDA approval – Impax Laboratories, Inc. and Watson Laboratories, Inc. – to eliminate the risk of competition for Opana ER and Lidoderm, in violation of the Federal Trade Commission Act. Opana ER is an extendedrelease opioid used to relieve moderate to severe pain. Lidoderm is a topical patch used to relieve pain associated with post-herpetic neuralgia, a complication of shingles. The FTC is seeking a court judgment declaring that the defendants’ conduct violates the antitrust laws, ordering the companies to disgorge their ill-gotten gains, and permanently barring them from engaging in similar anticompetitive behavior in the future. Teikoko Pharma USA and Teikoku Seiyaku Co., Ltd. agreed to a stipulated order resolving FTC charges.
In November 2016, the FTC voluntarily dismissed the complaint in this action. On January 23, 2017, the FTC refiled charges related to the Lidoderm agreements in federal court in California (Federal Trade Commission vs. Allergan plc; Watson Laboratories, Inc., et al) and refiled charges related to the Opana ER agreement in a Part 3 administrative proceeding. (In re Impax Laboratories, Inc.)
Type of Action
Federal
Last Updated
FTC Matter/File Number
141 0004
FTC Approves Modification of Final Order Related to Pfizer’s 2009 Acquisition of Wyeth
Date
Following a public comment period, the Federal Trade Commission has approved an application by Pfizer Inc. to modify the FTC’s January 2010 final order, which settled the FTC’s competition concerns...
FTC Chairwoman Releases 2015 Annual Highlights
Date
Federal Trade Commission Chairwoman Edith Ramirez released the FTC’s 2015 Annual Highlights today, featuring some of the agency’s key efforts to benefit consumers and promote competition over the past...
Pfizer Inc., a corporation, and Wyeth, a corporation, In the Matter of
The Commission challenged Pfizer Inc.’s proposed $68 billion acquisition of Wyeth and required significant divestitures to preserve competition in multiple U.S. markets for animal pharmaceuticals and vaccines. The proposed consent order remedies the anticompetitive effects the Commission believes are likely to result from the transaction in numerous markets for animal vaccines and animal pharmaceutical products. After a thorough investigation, the Commission concluded that the transaction does not raise anticompetitive concerns in any human health product markets.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
091 0053
Docket Number
C-4267
Prepared Statement of Maureen K. Ohlhausen: “Section 5 and ‘Unfair Methods of Competition’: Protecting Competition or Increasing Uncertainty?”
Date
By
Maureen K. Ohlhausen, Former Commissioner
File
Text of the Testimony
(97.93 KB)
1604001 Informal Interpretation
Date
Rule
Items 4(c) and 4(d)
UPDATE May 23, 2017: This no longer represents the position of the PNO. Please see https://www.ftc.gov/news-events/blogs/competition-matters/2016/11/reset…. If documents...
File
Original Image
(39.34 KB)
FTC Approves Modified Final Order for Hikma Pharmaceuticals PLC
Date
The Federal Trade Commission has approved a modified final order settling charges that Hikma Pharmaceuticals PLC’s acquisition of the rights to various drug products and related assets from Ben Venue...
FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm
Date
The Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay...
Displaying 2361 - 2380 of 4770